Literature DB >> 23649693

A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers.

Jun Yi Wang1, Randi J Hagerman, Susan M Rivera.   

Abstract

Approximately 40% of males with the fragile X premutation develop fragile X-associated tremor/ataxia syndrome after age 50. Although the thalamus and basal ganglia play a crucial role in movement disorders, their involvement in fragile X premutation carriers has not been systematically investigated. The current study characterized structural abnormalities associated with fragile X premutation carriers (with and without fragile X-associated tremor/ataxia syndrome) in the thalamus, caudate nucleus, putamen, and globus pallidus using T1-weighted and diffusion tensor imaging. Male premutation carriers with fragile X-associated tremor/ataxia syndrome showed significant volume atrophy and diffusion-weighted signal loss in all 4 structures compared with the control group. They also exhibited volume atrophy and diffusion-weighted signal loss in the thalamus and striatum compared with the premutation carriers without fragile X-associated tremor/ataxia syndrome. Importantly, many of the measurements exhibited robust correlations with symptom severity, with volume and diffusion-weighted imaging measurements displaying negative correlations and fractional anisotropy measurements displaying positive correlations. The current study demonstrated involvement of all 4 subcortical gray matter structures in fragile X-associated tremor/ataxia syndrome, with significant volume atrophy, and possible iron deposition indicated by the diffusion-weighted signal loss. The significant correlation between the subcortical measurements and symptom severity suggests the benefits of tracking structural changes in subcortical gray matter in future longitudinal studies for early detection and disease monitoring. © 2013 Movement Disorder Society.
Copyright © 2013 Movement Disorder Society.

Entities:  

Keywords:  diffusion tensor imaging; diffusion-weighted imaging; genetic disorder; iron dysregulation; neurodegeneration

Mesh:

Substances:

Year:  2013        PMID: 23649693      PMCID: PMC3785985          DOI: 10.1002/mds.25473

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  48 in total

Review 1.  Iron dysregulation in movement disorders.

Authors:  Petr Dusek; Joseph Jankovic; Weidong Le
Journal:  Neurobiol Dis       Date:  2012-01-12       Impact factor: 5.996

2.  Quantitative MR imaging of brain iron: a postmortem validation study.

Authors:  Christian Langkammer; Nikolaus Krebs; Walter Goessler; Eva Scheurer; Franz Ebner; Kathrin Yen; Franz Fazekas; Stefan Ropele
Journal:  Radiology       Date:  2010-09-15       Impact factor: 11.105

Review 3.  Imaging iron stores in the brain using magnetic resonance imaging.

Authors:  E Mark Haacke; Norman Y C Cheng; Michael J House; Qiang Liu; Jaladhar Neelavalli; Robert J Ogg; Asadullah Khan; Muhammad Ayaz; Wolff Kirsch; Andre Obenaus
Journal:  Magn Reson Imaging       Date:  2005-01       Impact factor: 2.546

Review 4.  Advances in functional and structural MR image analysis and implementation as FSL.

Authors:  Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

5.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI.

Authors:  P J Basser; C Pierpaoli
Journal:  J Magn Reson B       Date:  1996-06

6.  Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.

Authors:  Guangwei Du; Mechelle M Lewis; Martin Styner; Michele L Shaffer; Suman Sen; Qing X Yang; Xuemei Huang
Journal:  Mov Disord       Date:  2011-05-26       Impact factor: 10.338

7.  Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene.

Authors:  Ryu-ichiro Hashimoto; Siddharth Srivastava; Flora Tassone; Randi J Hagerman; Susan M Rivera
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

8.  Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers.

Authors:  James A Bourgeois; Andreea L Seritan; E Melina Casillas; David Hessl; Andrea Schneider; Ying Yang; Inderjeet Kaur; Jennifer B Cogswell; Danh V Nguyen; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

9.  Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.

Authors:  H Toledano-Alhadef; L Basel-Vanagaite; N Magal; B Davidov; S Ehrlich; V Drasinover; E Taub; G J Halpern; N Ginott; M Shohat
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

10.  A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome.

Authors:  Stela Filipovic-Sadic; Sachin Sah; Liangjing Chen; Julie Krosting; Edward Sekinger; Wenting Zhang; Paul J Hagerman; Timothy T Stenzel; Andrew G Hadd; Gary J Latham; Flora Tassone
Journal:  Clin Chem       Date:  2010-01-07       Impact factor: 8.327

View more
  17 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology.

Authors:  Jim Grigsby
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

Review 4.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

5.  White matter disease and cognitive impairment in FMR1 premutation carriers.

Authors:  Christopher M Filley; Mark S Brown; Karen Onderko; Megan Ray; Rachael E Bennett; Elizabeth Berry-Kravis; Jim Grigsby
Journal:  Neurology       Date:  2015-04-29       Impact factor: 9.910

6.  Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with FMR1 normal and premutation alleles.

Authors:  Jun Yi Wang; David Hessl; Flora Tassone; Kyoungmi Kim; Randi J Hagerman; Susan M Rivera
Journal:  Neurobiol Aging       Date:  2019-09-24       Impact factor: 4.673

7.  Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation.

Authors:  Jun Yi Wang; David Hessl; Randi J Hagerman; Tony J Simon; Flora Tassone; Emilio Ferrer; Susan M Rivera
Journal:  Neurobiol Aging       Date:  2017-03-18       Impact factor: 4.673

8.  Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome.

Authors:  Jeanelle Ariza; Craig Steward; Flora Rueckert; Matt Widdison; Robert Coffman; Atiyeh Afjei; Stephen C Noctor; Randi Hagerman; Paul Hagerman; Verónica Martínez-Cerdeño
Journal:  Brain Res       Date:  2014-12-09       Impact factor: 3.252

Review 9.  Understanding the neuropsychiatric phenotype of fragile X-associated tremor ataxia syndrome: a systematic review.

Authors:  R C Birch; K M Cornish; D R Hocking; J N Trollor
Journal:  Neuropsychol Rev       Date:  2014-05-15       Impact factor: 7.444

10.  Dystonia in a Female Fragile X Premutation Carrier.

Authors:  Victoria Ros-Castelló; Anna Latorre; Juan Álvarez-Linera; Juan C Martinez-Castrillo; Kailash P Bhatia; Isabel Pareés
Journal:  Mov Disord Clin Pract       Date:  2021-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.